Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D

The mega-round club of China’s oncology drugmakers is just getting started.

In the latest, Suzhou-based Tot Biopharm closed $102 million in Series B cash to fuel R&D of the 10 drugs in its pipeline.